^
5ms
Trial completion • Combination therapy • Metastases
|
FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
irinotecan • S95018 • Sym021 • Sym022
7ms
Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies (clinicaltrials.gov)
P1, N=78, Active, not recruiting, Symphogen A/S | N=148 --> 78 | Trial completion date: Jan 2025 --> Jun 2024
Enrollment change • Trial completion date • Combination therapy • Metastases
|
FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 mutation • FGFR2 mutation • FGFR2 fusion
|
irinotecan • S95018 • Sym021 • Sym022
9ms
Phase classification
|
FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 mutation • FGFR2 mutation • FGFR2 fusion
|
irinotecan • S95018 • Sym021 • Sym022
2years
Enrollment closed • Combination therapy
|
FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 mutation • FGFR2 mutation • FGFR2 fusion
|
irinotecan • S95018 • Sym021 • Sym022
over2years
Enrollment change • Trial primary completion date • Combination therapy
|
FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 mutation • FGFR2 mutation • FGFR2 fusion
|
irinotecan • S95018 • Sym021 • Sym022
almost3years
Enrollment open • Combination therapy
|
FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 mutation • FGFR2 mutation • FGFR2 fusion
|
irinotecan • S95018 • Sym021 • Sym022
over3years
Clinical • Enrollment change • Combination therapy
|
FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 mutation • FGFR2 mutation • FGFR2 fusion
|
irinotecan • S95018 • Sym021 • Sym022